Gram-Negative Infections | Current Treatment: Physician Insights | US | 2019

Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) market. Most inpatients are successfully treated empirically with such agents, making it difficult for branded products like Merck & Co.’s Zerbaxa, Allergan’s Avycaz, Melinta’s Vabomere and Baxdela, Achaogen’s Zemdri, Tetraphase’s Xerava, or Paratek’s Nuzyra to gain uptake in earlier lines of therapy. However, rising antimicrobial resistance rates have created the need for safer products to effectively treat drug-resistant GNIs, and our primary market research shows that activity against key drug-resistant pathogens is an important driver of brand use in this market. Furthermore, hospital-based ID specialists report shifts in how they treat GNIs in response to the growing drug resistance.

QUESTIONS ANSWERED

• What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
• How are physicians approaching the treatment of infections caused by drug resistant pathogens?
• Which clinical and nonclinical factors drive, and prevent, the prescribing of branded agents such as Zerbaxa, Avycaz, Vabomere, Zemdri, and Xerava?
•  What will be the impact of the recent approval of Vabomere, Zemdri, Xerava, and other new agents? What will drive use of these therapies, and in which populations will they be used? Which current agents will be most affected?

PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use, so you can create specific messaging around these treatment dynamics in order to more effectively
increase or defend your market position.

GEOGRAPHIES: United States

PRIMARY RESEARCH: Survey of 100 U.S. hospital based, infectious disease and critical care specialists

KEY DRUGS COVERED: Avycaz, Zerbaxa, Vabomere, Zemdri, Xerava, Nuzyra, Baxdela, and other key GNI drugs